[Innovative therapeutic approach to atrial fibrillation: AT1-receptor blocker].
Goette
A
A
Klinik für Kardiologie, Angiologie und Pneumologie, Otto-von-Guericke-Universitätsklinik Magdeburg. andreas.goette@medizin.uni-magdeburg.de
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000517:prevention & control; D004554:Electric Countershock; D006325:Heart Atria / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D009206:Myocardium / Q000473:pathology; D011322:Primary Prevention / Q000379:methods; D012084:Renin-Angiotensin System / Q000187:drug effects; D055502:Secondary Prevention
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors